mafosfamide has been researched along with abt-737 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Obaidi, M; Bhatia, R; Di Stasi, A; Erba, HP; Jamil, MO; Lamb, LS; Minagawa, K; Mineishi, S; Pereboeva, L; Salzman, D | 1 |
1 other study(ies) available for mafosfamide and abt-737
| Article | Year |
|---|---|
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
Topics: B7-H1 Antigen; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Caspase 9; Cell Engineering; Cell Line, Tumor; Cell Proliferation; Cellular Reprogramming; Clinical Trials as Topic; Cyclophosphamide; Cytotoxicity, Immunologic; Genetic Vectors; Humans; Interferon-gamma; Leukemia, Myeloid, Acute; Lysosomal-Associated Membrane Protein 1; Myeloid Cells; Nitrophenols; Piperazines; Primary Cell Culture; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; Sialic Acid Binding Ig-like Lectin 3; Sulfonamides; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2016 |